Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Concurrent temozolomide Clear all
Active, not recruiting Phase 1Phase 2 Interventional

A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

NCT01985087
View directory record Official record
Conditions
Glioblastoma
Interventions
Hypofractionated radiotherapy, Temozolomide
Radiation · Drug
Lead sponsor
University of Louisville
Other
Eligibility
70 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional Results available

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

NCT01400958
View directory record Official record
Conditions
Malignant Glioma
Interventions
Nuvigil®, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 1Phase 2 Interventional

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

NCT02046187
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
Ketogenic Diet, Radiation therapy, Temozolomide
Dietary Supplement · Radiation · Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 19, 2026, 10:28 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

NCT04752813
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation
Drug · Other · Radiation
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Santa Barbara, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Not applicable Interventional

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas

NCT01653834
View directory record Official record
Conditions
Glioblastoma
Interventions
Lymphocyte harvesting & reinfusion
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 19, 2026, 10:28 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

NCT04195139
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nivolumab, Temozolomide
Drug
Lead sponsor
University of Sydney
Other
Eligibility
65 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1 Interventional

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

NCT01849146
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
Adavosertib, Radiation Therapy, Temozolomide
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 19, 2026, 10:28 PM EDT
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161
View directory record Official record
Conditions
Glioblastoma, Gliomas
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01822275
View directory record Official record
Conditions
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
Interventions
Chemotherapy with Temodar., Radiation therapy
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 19, 2026, 10:28 PM EDT
Active, not recruiting Phase 3 Interventional

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

NCT00887146
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
271
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

NCT01478321
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
Interventions
Temozolomide, hypofractionated radiation therapy, bevacizumab, questionnaire administration
Drug · Radiation · Biological + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Lake Forest, Illinois • Naperville, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 19, 2026, 10:28 PM EDT
Not listed Phase 2 Interventional

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

NCT00492687
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, tamoxifen citrate, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
San Diego Pacific Oncology & Hematology Associates
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

NCT02573324
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414
Drug · Radiation
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
68
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1 Interventional

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

NCT00584883
View directory record Official record
Conditions
Brain Tumor
Interventions
ABT 510
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 1 Interventional

Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma

NCT02254954
View directory record Official record
Conditions
Glioblastoma
Interventions
Macitentan in combination with RT and TMZ
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 19, 2026, 10:28 PM EDT
Withdrawn Phase 2 Interventional

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

NCT03506139
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
External beam radiation therapy
Radiation
Lead sponsor
John M. Buatti
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1 Interventional

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

NCT02903069
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
MRZ, TMZ, RT, Optune
Drug · Radiation · Device
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 1 Interventional

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

NCT04541407
View directory record Official record
Conditions
Non Small Cell Lung Cancer, CNS Progression
Interventions
Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Early Phase 1 Interventional

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

NCT02490930
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma
Interventions
Fingolimod
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 19, 2026, 10:28 PM EDT
Completed Phase 2 Interventional

Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00274833
View directory record Official record
Conditions
CNS Tumor, Adult
Interventions
erlotinib hydrochloride, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
David Peereboom
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 1 Interventional

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT02530502
View directory record Official record
Conditions
Adult Glioblastoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide
Other · Biological · Radiation + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

NCT00068666
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
45
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Beech Grove, Indiana + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 19, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemoradiation for Resectable Glioblastoma

NCT04209790
View directory record Official record
Conditions
Glioblastoma, Surgery, High Grade Glioma
Interventions
Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
Radiation · Drug · Procedure
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 19, 2026, 10:28 PM EDT